AbCheck s.r.o., the multi antibody discovery platforms company, has entered into a research collaboration with Martinsried, Germany-based U3 Pharma GmbH. U3 Pharma is the antibody targeted cancer drug development affiliate of Daiichi Sankyo Co. Ltd., one of the top 20 leading pharmaceutical companies worldwide.
Under the agreement AbCheck will use its AbSieve discovery platform, which combines the company’s proprietary phage and yeast display technologies, to deliver antibodies against an undisclosed number of U3 Pharma targets. U3 Pharma, which has full rights to any antibodies selected, will pay AbCheck discovery fees and milestone payments. Other financial and deal terms are not disclosed.
“The selection of AbCheck by U3 Pharma is very important to us,” said Dr Volker Lang, managing director of AbCheck. “Entering into a research collaboration with the Company, a recognized specialist in innovative antibody-based therapeutics, further underlines the quality of AbCheck’s antibody discovery technologies and efficient processes that ensure the delivery of high quality GMP ready antibodies. Furthermore, this deal once again validates our exceptional business model, which has now been proven through partnerships with both pharma and biotech companies throughout the US and Europe.”
Dr Shoji Hirashima, CEO and managing director of U3 Pharma said: “AbCheck has a well-established technology-platform and defined processes for antibody drug discovery. We believe we will identify good drug candidate antibodies more efficiently through this collaboration with AbCheck.”